ArticleEuropean heart journal. Cardiovascular Imaging2026
Impact of rate-pressure product correction of myocardial blood flow on the prognostic relevance in patients with heart failure.
Article in European heart journal. Cardiovascular Imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimsQuantitative perfusion cardiac magnetic resonance (QP-CMR) allows estimation of myocardial blood flow (MBF) and myocardial perfusion reserve (MPR). Resting MBF values are often corrected for the rate-pressure product (RPP). We aimed to assess the effect of RPP correction on MBF values and the prognostic value of QP-CMR in patients with heart failure (HF). METHODS AND
resultsQP-CMR data from 641 prospectively recruited patients with HF and 184 healthy volunteers were analysed. Rest MBF was corrected for RPP (MBFcorr = rest MBFuncorr×10 000/RPP). Corrected MPR was defined as uncorrected stress MBF/rest MBFcorr. The primary endpoint was a composite of heart failure hospitalization (HFH) and all-cause mortality. RPP correction increased rest MBF and decreased MPR to a greater extent in healthy volunteers than in patients. During median follow-up of 3.5 years, 101 events occurred (55 deaths and 46 HFH). Patients who reached the primary endpoint had significantly higher rest MBFuncorr and lower MPRuncorr. Rest MBFuncorr (adjusted hazard ratio per 1 mL/g/min increase, 3.97, 95% confidence interval [CI] 1.93-8.16, P < 0.001) and MPRuncorr (adjusted hazard ratio per 1-unit increase, 0.74, 95% CI 0.57-0.95, P = 0.024) were significantly associated with the primary endpoint in univariate and multivariate models. After RPP correction, these associations were no longer significant. Kaplan-Meier analysis revealed significant differences in event-free survival for rest MBFuncorr (P = 0.005), MPRuncorr (P < 0.001), and MPRcorr (P = 0.044), but not for rest MBFcorr (P = 0.076).
conclusionUncorrected rest MBF and MPR by QP-CMR are independently predictive of adverse outcomes in patients with HF. RPP correction changes MBF and MPR values and attenuates their predictive value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.